Q1 25 EPS
$2.49
Q1 25 Revenue
$13.59B
vs S&P Since Q1 25
+2.2%
BEATING MARKET
AZN +32.1% vs S&P +30.0%
Market Reaction
Did AZN Beat Earnings? Q1 2025 Results
AstraZeneca opened 2025 on firm footing, posting Q1 revenue of $13.59 billion, up 10% at constant exchange rates, while core EPS climbed 21% to $2.49, reflecting broad momentum across its two largest business segments. The headline numbers were lifte… Read more AstraZeneca opened 2025 on firm footing, posting Q1 revenue of $13.59 billion, up 10% at constant exchange rates, while core EPS climbed 21% to $2.49, reflecting broad momentum across its two largest business segments. The headline numbers were lifted in part by a notably lower core tax rate of 16%, down from 21% a year earlier, following settlements with tax authorities that reduced prior-period liabilities, though management expects the full-year rate to normalize to between 18% and 22%. Oncology remained the engine of growth, with the segment reaching $5.64 billion as Enhertu surged 34% at constant exchange rates and Imfinzi grew 16%, buoyed by expanding indications in liver, biliary tract, and lung cancers. Five positive Phase III readouts, including DESTINY-Breast09 for Enhertu in first-line HER2-positive metastatic breast cancer, added pipeline credibility to the financial results. AstraZeneca reiterated its full-year 2025 guidance for high single-digit revenue growth and low double-digit core EPS growth at constant exchange rates.
Key Takeaways
- • Double-digit revenue growth in Oncology (13% CER) and BioPharmaceuticals (12% CER)
- • Strong demand and new indication expansion across key oncology medicines
- • Farxiga growth driven by heart failure and CKD indications supported by cardiorenal guidelines
- • Rapid Enhertu adoption post-NRDL enlistment in China for HER2-positive and HER2-low breast cancer
- • Tezspire sustained demand growth in severe asthma with launch momentum across multiple markets
- • Breztri fastest-growing medicine within expanding FDC triple class for COPD
- • Ultomiris growth from patient demand and conversion from Soliris across all indications
- • Lower Core tax rate of 16% due to timing of settlements with tax authorities
- • Revenue growth across all major geographic regions
AZN YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
AZN Revenue by Segment
With YoY comparisons, source: SEC Filings
AZN Revenue by Geography
With YoY comparisons, source: SEC Filings
“Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company.”
— Pascal Soriot, Q1 2025 Earnings Press Release
AZN Earnings Trends
AZN vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
AZN EPS Trend
Earnings per share: estimate vs actual
AZN Revenue Trend
Quarterly revenue: estimate vs actual
AZN Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $2.58 | — | $15.29B | — |
| Q4 25 FY | — | $2.12 | — | $15.50B | +1.26% |
| FY Full Year | $4.59 | $9.16 | +99.72% | $58.74B | +0.33% |
| Q3 25 FY | — | $2.38 | — | $15.19B | — |
| FY Full Year | $4.59 | — | — | — | — |
| Q1 25 | — | $2.49 | — | $13.59B | — |
| Q4 24 FY | — | $2.09 | — | $14.89B | — |
| FY Full Year | — | $8.21 | — | $54.07B | — |